×
For best experience we recommend to activate Javascript in your browser.
TAB1 antibody (Ser423)
This Rabbit Polyclonal antibody specifically detects TAB1 in WB and ELISA. It exhibits reactivity toward Human.
Quick Overview for TAB1 antibody (Ser423) (ABIN2370886)
Target
See all TAB1 Antibodies
TAB1
(TGF-beta Activated Kinase 1/MAP3K7 Binding Protein 1 (TAB1))
Reactivity
All reactivities for TAB1 antibodies
Human
Host
All hosts for TAB1 antibodies
Rabbit
Clonality
All clonalities for TAB1 antibodies
Polyclonal
Conjugate
All conjugates for TAB1 antibodies
This TAB1 antibody is un-conjugated
Application
All applications for TAB1 antibodies
Western Blotting (WB), ELISA
Product Details anti-TAB1 Antibody
(hide)
Binding Specificity
All epitopes for TAB1 antibodies
Ser423
Cross-Reactivity
Human
Cross-Reactivity (Details)
Calculated cross reactivity: Hu
Characteristics
TAB1 (Ser423) (TGF-beta-activated Kinase 1 and MAP3K7-binding Protein 1, TGF-beta-activated Kinase 1-binding Protein 1, TAK1-binding Protein 1, 3'-Tab1, Mitogen-activated Protein Kinase Kinase Kinase 7-interacting Protein 1, MAP3K7IP1)
Purification
Purified by immunoaffinity chromatography.
Immunogen
Synthetic peptide selected from the amino acid residues surrounding S423 of human MAP3K7IP1 (KLH).
Isotype
IgG
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working conditions should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Buffer
Supplied as a liquid in PBS, 0.09 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Storage Comment
-20°C
Target Details for TAB1
(hide)
Target
TAB1
(TGF-beta Activated Kinase 1/MAP3K7 Binding Protein 1 (TAB1))
Alternative Name
TAB1
NCBI Accession
NP_006107
UniProt
Q15750
Pathways
TLR Signaling , Fc-epsilon Receptor Signaling Pathway , Activation of Innate immune Response , Toll-Like Receptors Cascades
Recently viewed
(hide)
Chat with us , powered by LiveChat